I wrote a detailed article on Amira Nature Foods (NYSE: ANFI) a month ago, so please read it if before watching the below video if you are not familiar with ANFI.
Since then, ANFI’s stock price has increased by about 30% and I wanted to give an update about my views on ANFI’s fair value and fair market value.
Additionally, I have analyzed the real value of ANFI’s land plots, the 20.3 acres in Guargon, South of New Dehli, and 48 acres in Karnal, north of New Dehli. I must say that for the first time I agree with the short attacks that have plagued ANFI in the last few years. The balance sheet values and the real values don’t match. However, my calculations show far higher values than those on the balance sheet. Please enjoy the video and I look forward to your comments and insights about ANFI.
Disclosure: I am/we are long ANFI.
I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it. I have no business relationship with any company whose stock is mentioned in this article.
Hot Value Stocks For 2018: Silicon Graphics International Corp(SGI)
- [By Peter Graham]
A long term performance chart shows Cray Incstill and by far outperforming other supercomputer players likelarge caps International Business Machines Corp (NYSE: IBM) andHewlett-Packard Company (NYSE: HPQ) plus small cap Silicon Graphics International Corp (NASDAQ: SGI):
Hot Value Stocks For 2018: Peugeot S.A. (PUGOY)
- [By SEEKINGALPHA.COM]
Yes, you read that correct! General Motors (NYSE: GM) will probably not settle for just a new 52-week high and will aim to take out the 2013 peak of $41.85. With talks about the Opel sellout to PSA Group (OTCPK:PEUGF) (OTCPK:PUGOY) progressing at a rate much faster than I had anticipated, a (likely) deal announcement on Monday will pave the way for new all-time highs.
- [By John Rosevear]
It’s official: General Motors (NYSE:GM) will sell its long-troubled Opel subsidiary to French automaker Peugeot S.A. (NASDAQOTH:PUGOY) for about $2.3 billion, in a deal expected to close later this year.
- [By Adam Levine-Weinberg]
Now, the General is thinking about ditching Europe for good by selling its European operations to French automaker Peugeot (NASDAQOTH:PUGOY). As long as Peugeot is willing to pay a reasonable price, selling Opel is GM’s best course of action.
Hot Value Stocks For 2018: Sarepta Therapeutics, Inc.(SRPT)
- [By Lisa Levin]
Sarepta Therapeutics Inc (NASDAQ: SRPT) shares were also up, gaining 16 percent to $47.52 following the announcement of positive results in its study for the treatment of Duchenne Muscular Dystrophy.
- [By Ben Levisohn]
Skorney’s namesVertex Pharmaceuticals (VRTX),Sarepta Therapeutics (SRPT), and Curis (CRIS) his top biotech picks for 2017, while Ulz chosesBioMarin Pharmaceutical (BMRN) andParatek Pharmaceuticals (PRTK).
- [By Johanna Bennett]
Will healthinsurers pay for Sarepta Therapeutics (SRPT) Exondys 51?
Thats a question that several analysts have weighed on today. It appears that payors are still actively evaluating and reevaluating coverage of the Duchenne muscular dystrophy drug Exondys 51.
Approved by the FDA in September, the drug has met with widespread pushback from insurers like Anthem (ANTM), Humana (HUM) and UnitedHealth Group (UNH) amid concerns about its efficacy. So while Sareptas share price has more than doubled over the past 12 months, it has made a sharp retreat, falling 50% to just under $32 a share since hitting a record high $63.73 a share in late September.
But Cowen analyst Ritu Baral says the tide maybe turning, arguing that coverage denials wont be permanent.
As SRPT management and our Neuromuscular Disease panelist indicated to us at our recent Healthcare Conference, payor discussions are continuing regarding Exondys 51 with manageable, increasingly positive feedback. Of the major plans we have seen coverage policies released for, only Anthem (including Blue Cross Blue Shield) had previously denied coverage of Exondys, though patients could petition for coverage via a standard appeal process (see further below). Based on their February Specialty Pharmacy Medical Management Prior Authorization Drug List, it appears Anthem will add Exondys 51 to its prior auth list as of 5/1. We think this is encouraging and indicative of the evolving payor landscape surrounding Exondys 51 and more broadly, DMD. Anthem’s pick-up, together with those such as United, which started coverage on 2/1, support the idea of accelerating new patient starts, suggested by SRPT last week at our Healthcare Conference.
…But Coverage Denials Persist (For Now), Especially Among Non-Ambulatory Patients. While we think the overwhelming majority of amenable patients will eventually be covered for Exondys 51, we do note several social media anecdote
- [By Chris Lange]
Sarepta Therapeutics, Inc. (NASDAQ: SRPT) saw its shares make a handy gain on Tuesday following its presentation at the JPMorgan Healthcare Conference. The companys Duchenne muscular dystrophy (DMD) drug, Exondys 51, generated better than expected sales clocking in at $5.4 million in the fourth quarter. Previously, this DMD treatment was approved by the FDA just as recently as September 2016.